Epidermolysis bullosa aquisita following immune-checkpoint inhibitor treatment for metastatic melanoma

Jane O'Connor; Shuai Zhang; Joao R Galante; John Mee; Kristina Semkova; Rosemeen Parkar; Richard Groves

doi:10.1111/ced.15161

Epidermolysis bullosa aquisita following immune-checkpoint inhibitor treatment for metastatic melanoma

Clin Exp Dermatol. 2022 Jun;47(6):1198-1199. doi: 10.1111/ced.15161. Epub 2022 Apr 26.

Authors

Jane O'Connor¹, Shuai Zhang², Joao R Galante², John Mee¹, Kristina Semkova¹, Rosemeen Parkar², Richard Groves¹

Affiliations

¹ St John's Institute of Dermatology, Guy's Hospital, Guy's & St Thomas' NHS Foundation Trust, London, UK.
² Department of Medical Oncology, Kent Oncology Centre, Maidstone General Hospital, Maidstone and Tunbridge Wells NHS Trust, Maidstone, Kent, UK.

PMID: 35244234
DOI: 10.1111/ced.15161

Abstract

A case of epidermolysis bullosa aquisita following immunotherapy for melanoma. This adds to the repertoire of subepidermal blistering disorders documented following immune checkpoint therapy.

Publication types

Case Reports
Letter

MeSH terms

Epidermolysis Bullosa Acquisita*
Epidermolysis Bullosa* / pathology
Humans
Immune Checkpoint Inhibitors / adverse effects
Immunologic Factors / therapeutic use
Melanoma* / drug therapy
Neoplasms, Second Primary*
Skin Diseases, Vesiculobullous*

Substances

Immune Checkpoint Inhibitors
Immunologic Factors